148 related articles for article (PubMed ID: 20960108)
1. Heparanase-1 and Cyclooxygenase-2: prognostic indicators of malignancy in pheochromocytomas.
Zhu Y; He HC; Yuan F; Zhang J; Rui WB; Zhao JP; Shen ZJ; Ning G
Endocrine; 2010 Aug; 38(1):93-9. PubMed ID: 20960108
[TBL] [Abstract][Full Text] [Related]
2. Differential heparanase-1 expression in malignant and benign pheochromocytomas.
Quiros RM; Kim AW; Maxhimer J; Gattuso P; Xu X; Prinz RA
J Surg Res; 2002 Nov; 108(1):44-50. PubMed ID: 12443714
[TBL] [Abstract][Full Text] [Related]
3. Survivin: a novel neuroendocrine marker for pheochromocytoma.
Koch CA; Vortmeyer AO; Diallo R; Poremba C; Giordano TJ; Sanders D; Bornstein SR; Chrousos GP; Pacak K
Eur J Endocrinol; 2002 Mar; 146(3):381-8. PubMed ID: 11888845
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.
Salmenkivi K; Haglund C; Ristimäki A; Arola J; Heikkilä P
J Clin Endocrinol Metab; 2001 Nov; 86(11):5615-9. PubMed ID: 11701743
[TBL] [Abstract][Full Text] [Related]
5. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
6. Expression of galectin-3, nm-23, and cyclooxygenase-2 could potentially discriminate between benign and malignant pheochromocytoma.
Saffar H; Sanii S; Heshmat R; Haghpanah V; Larijani B; Rajabiani A; Azimi S; Tavangar SM
Am J Clin Pathol; 2011 Mar; 135(3):454-60. PubMed ID: 21350102
[TBL] [Abstract][Full Text] [Related]
7. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
8. The significance of angiogenesis in malignant pheochromocytomas.
Rooijens PP; de Krijger RR; Bonjer HJ; van der Ham F; Nigg AL; Bruining HA; Lamberts SW; van der Harst E
Endocr Pathol; 2004; 15(1):39-45. PubMed ID: 15067175
[TBL] [Abstract][Full Text] [Related]
9. [Role of immunohistochemical study of extracellular matrix components in the estimation of the malignant potential of adrenal pheochromocytomas].
Bezuglova TV; Poliakova GA; Kazantseva IA
Arkh Patol; 2008; 70(6):19-21. PubMed ID: 19227276
[TBL] [Abstract][Full Text] [Related]
10. [Pheochromocytomas in adrenal medulla or extra-adrenal and multiple endocrine neoplasms:a clinicopathologic analysis of 181 cases].
Jiang CX; Zeng Z; Wang T; Liu X; Liu R; Li Y
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):762-6. PubMed ID: 22336161
[TBL] [Abstract][Full Text] [Related]
11. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
12. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
[TBL] [Abstract][Full Text] [Related]
15. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors.
Yon L; Guillemot J; Montero-Hadjadje M; Grumolato L; Leprince J; Lefebvre H; Contesse V; Plouin PF; Vaudry H; Anouar Y
J Clin Endocrinol Metab; 2003 Jun; 88(6):2579-85. PubMed ID: 12788858
[TBL] [Abstract][Full Text] [Related]
16. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66.
Guillemot J; Thouënnon E; Guérin M; Vallet-Erdtmann V; Ravni A; Montéro-Hadjadje M; Lefebvre H; Klein M; Muresan M; Seidah NG; Anouar Y; Yon L
J Mol Endocrinol; 2012 Apr; 48(2):115-27. PubMed ID: 22217803
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors for malignant pheochromocytoma: analysis of 136 patients.
Feng F; Zhu Y; Wang X; Wu Y; Zhou W; Jin X; Zhang R; Sun F; Kasoma Z; Shen Z
J Urol; 2011 May; 185(5):1583-90. PubMed ID: 21419457
[TBL] [Abstract][Full Text] [Related]
18. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome.
Salmenkivi K; Heikkilä P; Liu J; Haglund C; Arola J
APMIS; 2003 Apr; 111(4):458-64. PubMed ID: 12780519
[TBL] [Abstract][Full Text] [Related]
19. [Distinction between benign and malignant pheochromocytomas].
Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 expression correlates with phaeochromocytoma malignancy: evidence for a Bcl-2-dependent mechanism.
Cadden IS; Atkinson AB; Johnston BT; Pogue K; Connolly R; McCance D; Ardill JE; Russell CF; McGinty A
Histopathology; 2007 Dec; 51(6):743-51. PubMed ID: 17916073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
